What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
James R. Cerhan spends much of his time researching Internal medicine, Risk factor, Lymphoma, Prospective cohort study and Odds ratio.
His Internal medicine research is multidisciplinary, incorporating elements of Endocrinology and Oncology.
His Risk factor research is multidisciplinary, incorporating perspectives in Body mass index, Environmental health, Cancer registry, Gynecology and Cohort.
His Lymphoma course of study focuses on Chronic lymphocytic leukemia and Single-nucleotide polymorphism, Locus, B cell and Genome-wide association study.
His work carried out in the field of Prospective cohort study brings together such families of science as Vitamin D and neurology, Absolute risk reduction, Confounding and Hazard ratio.
His Odds ratio research incorporates themes from Epidemiology, Case-control study, Allele, Allele frequency and Confidence interval.
His most cited work include:
- Body-Mass Index and Mortality among 1.46 Million White Adults (1564 citations)
- Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents (887 citations)
- Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing (726 citations)
What are the main themes of his work throughout his whole career to date?
James R. Cerhan mainly investigates Internal medicine, Oncology, Lymphoma, Immunology and Cancer.
Prospective cohort study, Odds ratio, Risk factor, Follicular lymphoma and Diffuse large B-cell lymphoma are among the areas of Internal medicine where James R. Cerhan concentrates his study.
His studies in Prospective cohort study integrate themes in fields like Relative risk and Cohort.
The concepts of his Risk factor study are interwoven with issues in Body mass index, Incidence, Epidemiology, Cohort study and Gynecology.
His Oncology study also includes fields such as
- Haplotype and Candidate gene most often made with reference to Single-nucleotide polymorphism,
- Proportional hazards model which connect with Hazard ratio.
His Lymphoma study combines topics from a wide range of disciplines, such as Gastroenterology, Cancer research and Surgery.
He most often published in these fields:
- Internal medicine (58.30%)
- Oncology (30.04%)
- Lymphoma (29.80%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (58.30%)
- Lymphoma (29.80%)
- Oncology (30.04%)
In recent papers he was focusing on the following fields of study:
James R. Cerhan focuses on Internal medicine, Lymphoma, Oncology, Diffuse large B-cell lymphoma and Follicular lymphoma.
His research brings together the fields of Gastroenterology and Internal medicine.
His Lymphoma research incorporates elements of Cancer, Survival rate, Quality of life, Biopsy and Disease.
The various areas that James R. Cerhan examines in his Oncology study include Odds ratio, International Prognostic Index and Cohort.
He combines subjects such as Cancer research and Clinical trial with his study of Diffuse large B-cell lymphoma.
His Hazard ratio study integrates concerns from other disciplines, such as Proportional hazards model and Cohort study.
Between 2017 and 2021, his most popular works were:
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (447 citations)
- Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. (156 citations)
- A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts (71 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
James R. Cerhan mainly focuses on Internal medicine, Lymphoma, Oncology, Follicular lymphoma and Diffuse large B-cell lymphoma.
All of his Internal medicine and Cohort study, Prospective cohort study, Odds ratio, Proportional hazards model and Cancer investigations are sub-components of the entire Internal medicine study.
In his study, B symptoms, Epidemiology, Response rate and Family medicine is inextricably linked to Cohort, which falls within the broad field of Prospective cohort study.
His research in Lymphoma intersects with topics in Survival rate, Cancer research and Hazard ratio.
His Oncology study combines topics in areas such as Young adult, Hematology, Disease and Chronic lymphocytic leukemia.
His Primary Mediastinal Large B-Cell Lymphoma study, which is part of a larger body of work in Diffuse large B-cell lymphoma, is frequently linked to Asterisk, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
